Dual PI3K/mTOR inhibitor with reduced brain penetration for use in oncology or other therapeutic areas.
Xemperia flag-ship project is a PCR-based blood test for breast cancer screening.The technology can be adapted to other cancers, immune, inflammatory and cardiovascular diseases.Xemperia's pipeline also includes DNA based nansensors for the ultrasensitive detection of nucleic acids.